BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 27377973)

  • 21. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
    Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
    Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
    J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
    Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
    Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 27. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway.
    Zhang G; Jin C; Zhu Y; Fu F; Wang G; Li S
    Life Sci; 2020 Dec; 263():118485. PubMed ID: 33017573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.
    Li T; Zhang Q; Zhang J; Yang G; Shao Z; Luo J; Fan M; Ni C; Wu Z; Hu X
    BMC Cancer; 2014 Feb; 14():96. PubMed ID: 24529079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
    Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
    Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
    Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
    Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
    Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
    Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
    Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.